Avalo Therapeutics (NASDAQ:AVTX) CFO Christopher Ryan Sullivan Sells 7,980 Shares

Avalo Therapeutics, Inc. (NASDAQ:AVTX) CFO Christopher Ryan Sullivan sold 7,980 shares of Avalo Therapeutics stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $17.15, for a total transaction of $136,857.00. Following the completion of the sale, the chief financial officer owned 17,338 shares in the company, valued at approximately $297,346.70. This trade represents a 31.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christopher Ryan Sullivan also recently made the following trade(s):

• On Wednesday, April 1st, Christopher Ryan Sullivan sold 7,979 shares of Avalo Therapeutics stock. The stock was sold at an average price of $16.77, for a total transaction of $133,807.83.

Avalo Therapeutics Price Performance

Avalo Therapeutics stock remained flat at $17.76 during midday trading on Friday. 1,109,141 shares of the company were exchanged, compared to its average volume of 845,897. Avalo Therapeutics, Inc. has a 1 year low of $3.39 and a 1 year high of $20.72. The company has a market capitalization of $404.75 million, a P/E ratio of -3.10 and a beta of 0.93. The business has a 50-day moving average of $15.50 and a two-hundred day moving average of $15.91.

Avalo Therapeutics (NASDAQ:AVTX) last posted its quarterly earnings data on Monday, March 23rd. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($1.54) by $1.17. The firm had revenue of $0.06 million for the quarter, compared to analysts’ expectations of ($0.21) million. On average, research analysts forecast that Avalo Therapeutics, Inc. will post -19.07 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Avalo Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Velan Capital Investment Management LP grew its holdings in Avalo Therapeutics by 38.4% in the 2nd quarter. Velan Capital Investment Management LP now owns 154,972 shares of the company’s stock valued at $773,000 after buying an additional 43,000 shares in the last quarter. Patient Square Capital LP acquired a new stake in shares of Avalo Therapeutics in the 3rd quarter worth $1,271,000. Cantor Fitzgerald L. P. purchased a new position in shares of Avalo Therapeutics during the 3rd quarter worth $1,083,000. Boothbay Fund Management LLC boosted its position in shares of Avalo Therapeutics by 1,916.6% during the 3rd quarter. Boothbay Fund Management LLC now owns 228,297 shares of the company’s stock valued at $2,902,000 after acquiring an additional 216,976 shares during the last quarter. Finally, Ally Bridge Group NY LLC acquired a new position in shares of Avalo Therapeutics during the 3rd quarter valued at about $2,264,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. HC Wainwright increased their price objective on Avalo Therapeutics from $25.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, March 25th. Mizuho raised shares of Avalo Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. Guggenheim started coverage on shares of Avalo Therapeutics in a report on Monday, February 2nd. They set a “buy” rating and a $50.00 target price for the company. BTIG Research reiterated a “buy” rating and issued a $40.00 target price on shares of Avalo Therapeutics in a research report on Tuesday, March 24th. Finally, Wall Street Zen upgraded shares of Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Sunday, March 29th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $42.25.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.